3D-printed corneal implants could ease donor scarcity and restore sight
Researchers have developed a 3D bioprinting method that creates corneal implants from lab-grown human cells, potentially addressing the global shortage of donor tissue. The technology produces a transparent, layered structure resembling a natural cornea, and an early-stage safety trial is currently underway. This approach could offer an alternative to traditional transplants that rely on deceased donors.
The bioprinting process uses lab-grown human cells to construct a transparent, layered implant that mimics the structure of a natural cornea. Precise Bio, the company behind the technology, reports that a single donor's corneal tissue can yield hundreds of implants through this method, dramatically multiplying the impact of each donation.
Currently, transplantable corneas must be recovered from deceased donors within hours of death, screened, and used within roughly two weeks. This tight window, combined with limited donor availability, leaves many patients without access. The new approach could bypass these constraints by manufacturing tissue on demand.
If proven safe and effective, bioprinted corneas could significantly expand access to sight-restoring surgery for the millions affected by corneal blindness worldwide. Patients in regions with scarce donor tissue may no longer face years-long waiting lists, and the technology could reduce dependence on deceased donors. However, early-stage trials remain limited, and broader availability would depend on regulatory approval, manufacturing scale-up, and cost considerations that are not